Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort
Journal of Thrombosis and Haemostasis · 2026-07 · 24 (7) · 2567-2578
DOI: 10.1016/j.jtha.2026.04.002 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-07. Verfasst von Jérémy Zordan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse University, Toulouse, France. Electronic address: zordan.j@chu-toulouse.fr. Hauptthemen laut MEDLINE: Benzoates, Pyrazoles, Hydrazines, Thrombopoietin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hôpitaux de Toulouse, Université de Toulouse.
Abstract (Originalsprache)
BACKGROUND: Thrombopoietin receptor agonists (TPO-RAs) have been identified as a risk factor for thrombosis in immune thrombocytopenia. A potential risk difference between eltrombopag and romiplostim (the only TPO-RAs available in France) is unknown and may be due to pharmacological differences. OBJECTIVES: We aimed to compare the risk of thrombosis between eltrombopag and romiplostim in adult patients with primary immune thrombocytopenia. METHODS: We performed a target trial emulation using the French national healthcare database. Patients exposed to first-line TPO-RAs were followed until the first hospitalization for thrombosis, discontinuation of TPO-RAs, death, or the end of follow-up at 1 year. We used inverse probability of treatment weighting and performed Cox proportional hazards models with time-varying adjustment. RESULTS: Between 2011 and 2022, 2761 and 949 patients were included in the eltrombopag and romiplostim groups, respectively. Patients in the romiplostim group were older and had more risk factors for thrombosis. The 1-year weighted cumulative incidence of thrombosis was 5.1% (95% CI, 3.6%-6.6%) with eltrombopag and 1.9% (95% CI, 1.0%-2.7%) with romiplostim. The adjusted hazard ratio for eltrombopag vs romiplostim was 1.93 (95% CI, 1.11-3.34) at 1 year. No significant difference was observed in the first 6 months, but emerged thereafter due to a few events. Results were similar for venous and arterial thrombosis when considered separately. The risk difference was the greatest in patients aged ≥75 years. CONCLUSION: Eltrombopag was associated with a greater risk of thrombosis than romiplostim after 6 months of exposure, particularly in elderly patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse University, Toulouse, France. Electronic address: zordan.j@chu-toulouse.fr.
- Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse University, Toulouse, France; Department of Internal Medicine, Referral Center for Autoimmune Cytopenia, Toulouse University Hospital, Toulouse…
- Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse University, Toulouse, France; Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse University, Toulouse, France.
Förderung
- Hôpitaux de Toulouse
- Université de Toulouse
Zitieren
APA
Zordan, J., Zadro, Y., Sommet, A., Lapeyre-Mestre, M., Moulis, G., & Lafaurie, M. (2026). Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort. Journal of Thrombosis and Haemostasis, 24(7), 2567-2578. https://doi.org/10.1016/j.jtha.2026.04.002
Vancouver
Zordan J, Zadro Y, Sommet A, Lapeyre-Mestre M, Moulis G, Lafaurie M. Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort. Journal of Thrombosis and Haemostasis. 2026;24(7):2567-2578. doi:10.1016/j.jtha.2026.04.002
BibTeX
@article{Zordan2026,
author = {Zordan, Jérémy and Zadro, Yoann and Sommet, Agnès and Lapeyre-Mestre, Maryse and Moulis, Guillaume and Lafaurie, Margaux},
title = {Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {7},
pages = {2567--2578},
doi = {10.1016/j.jtha.2026.04.002}
}
EUVIMED